'Doubt Ranbaxy claim that Mohali product filings not hit'

The question that needs to be resolved is what exactly is happening in terms of product filing and why is Ranbaxy saying that the product filings have not been impacted, says Vikas Dandekar, India Bureau Chief, PharmAsiaNews.Com.

Ailing pharma sector needs uniform drug standards: Ranbaxy

Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.

'India to lead global growth; bet on financial services'

Ajay Piramal says that Indian growth will be higher than the rest of the world soon and adds that the financial services sector is ripe for investment with lucrative returns on offer.

'Adulteration' defined differently in US and India: Ranbaxy

Arun Sawhney, managing director and chief executive officer, Ranbaxy continues to deny any wrong doing. He says the USFDA's ban on its products is due to different definitions of what is 'adulterated' in the US and in India.

Setting things right, not aware of DCGI probe: Ranbaxy

Agreeing to past misdeeds, Ranbaxy Laboratories says that the company is taking measure to set things right but cliams to be unaware of DCGI probe.

Not impacted by Ranbaxy's negative news: Alembic Pharma

Ranbaxy shares declined a further 2 percent on Wednesday morning after a media report said a prominent hospital in Mumbai had advised doctors to stop using the pharma company's drugs.

Will end 2012 with higher sales, profits: Ranbaxy

Ranbaxy managing director and chief executive Arun Sawhney told CNBC-TV18 that the pharmaceutical company would end fiscal 2012 with better sales and profits

Ranbaxy to have 30% mkt share for Lipitor: PharmAsiaNews

Vikas Dandekar of PharmAsiaNews.com tells CNBC-TV18 that the US FDA approval for Lipitor is definitely going to be a big positive for Ranbaxy.

Lipitor is biggest catalyst to Ranbaxy's growth: Expert

Chirag Talati, pharma analyst at Espirito Santo Securities tells CNBC-TV18 that Ranbaxy is most likely set to go ahead with the launch of the generic version of Lipitor, but how much market share it commands needs to be watched.

Blocking Ranbaxy's launch of cholesterol drug, where is the logic?

The US Foods and Drugs Administration (USFDA) will be sued by the US pharmaceutical company Mylan Inc, for an injunction on the launch of Ranbaxy’s cholesterol treatment drug Aricept, which is a generic version of Pfizer’s Lipitor.